20 completed. 20 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Completed 20 |
| Phase 2 | 1 | Completed 1 |
Follow rizatriptan: new trials by email Literature Review of rizatriptan trials Research Report on rizatriptan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine Rizatriptan 10 mg + Naproxen 550mg, Maxalt 10Mg Tablet, Flanax 550mg - Migraine | Phase 3 | Completed | Eurofarma Laboratorios S.A. | 2068 | 2022-12-30 | 2026-10-26 |
| Initiating Early Control of Migraine Pain and Associated Symptoms AXS-07 (MoSEIC meloxicam and rizatriptan), Placebo - Migraine | Phase 3 | Completed | Axsome Therapeutics, Inc. | 302 | 2019-10-08 | 2026-01-28 |
| Maximizing Outcomes in Treating Acute Migraine AXS-07 (MoSEIC meloxicam and rizatriptan), Meloxicam, Rizatriptan - Migraine | Phase 3 | Completed | Axsome Therapeutics, Inc. | 1594 | 2019-03-04 | 2023-08-24 |
| Rizatriptan for Episodic Dizziness in Vestibular Migraine Rizatriptan, Placebo - Vestibular Migraine, Migrainous Vertigo | Phase 2 / Phase 3 | Completed | Robert W. Baloh | 223 | 2014-12-01 | 2021-11-04 |
| A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3) rizatriptan benzoate - Acute Migraine With or Without Aura in Adolescents | Phase 3 | Completed | Organon and Co | 674 | 2009-12-01 | 2024-04-22 |
| A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7) rizatriptan, placebo - Migraine, Acute | Phase 3 | Completed | Organon and Co | 1382 | 2009-11-30 | 2024-05-07 |
| A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087) rizatriptan, Comparator: Placebo, Comparator: Sumatriptan - Acute Migraine | Phase 3 | Completed | Organon and Co | 109 | 2009-06-10 | 2024-05-10 |
| A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis rizatriptan benzoate, Comparator: placebo - Migraine | Phase 3 | Completed | Organon and Co | 108 | 2009-03-24 | 2024-05-23 |
| Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081) Comparator: rizatriptan benzoate, Comparator: Placebo - Migraine | Phase 3 | Completed | Organon and Co | 207 | 2007-10-03 | 2024-04-22 |
| Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache Maxalt 10mg MLT plus Caffeine 75mg, Maxalt 10mg MLT plus Placebo, Placebo + Placebo - Migraine With Aura, Migraine Without Aura | Phase 3 | Completed | Diamond Headache Clinic | 50 | 2007-04-01 | 2012-04-25 |
| Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012) Telcagepant 300 mg soft gel capsules, Telcagepant 280 mg tablets, Rizatriptan 10 mg tablets - Migraine | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1068 | 2007-02-21 | 2018-10-17 |
| Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071) MK0462, rizatriptan benzoate / Duration of Treatment -1 day, Comparator: placebo / Duration of Treatment - 1 day - Migraine | Phase 3 | Completed | Organon and Co | 393 | 2005-05-27 | 2024-08-14 |
| Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072) MK0462, rizatriptan benzoate / Duration of Treatment -1day, Comparator: placebo / Duration of Treatment - 1 day - Migraine | Phase 3 | Completed | Organon and Co | 393 | 2005-05-27 | 2024-08-14 |
| Study to Test an Approved Product in the Early Treatment of Migraine (0462-066) MK0462, rizatriptan benzoate / Duration of Treatment: 1day, Comparator: placebo / Duration of Treatment: 1 day - Migraine | Phase 3 | Completed | Organon and Co | 167 | 2004-10-21 | 2024-08-14 |
| Study to Test an Approved Product in the Early Treatment of Migraine (0462-065) MK0462, rizatriptan benzoate / Duration of Treatment: 1day, Comparator: placebo / Duration of Treatment: 1 day - Migraine | Phase 3 | Completed | Organon and Co | 529 | 2004-08-17 | 2024-08-14 |
| Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030) rizatriptan benzoate, Comparator: sumatriptan, Comparator: Placebo - Migraine Headache | Phase 3 | Completed | Organon and Co | 1268 | 1995-09-01 | 2022-02-03 |
| MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029) rizatriptan benzoate (MK0462), Comparator: sumatriptan, Comparator: Placebo - Migraine Headache | Phase 3 | Completed | Organon and Co | 933 | 1995-08-01 | 2022-02-03 |
| Treatment of Multiple Attacks of Acute Migraine (0462-025) rizatriptan benzoate, Comparator: Placebo - Migraine Headache | Phase 3 | Completed | Organon and Co | 473 | 1995-04-01 | 2022-02-03 |
| Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029) Rizatriptan 5 mg, Rizatriptan 10 mg, Standard Care - Migraine Disorders | Phase 3 | Completed | Organon and Co | 1959 | 1995-03-01 | 2022-02-03 |
| MK0462 in Treatment of Migraine With Recurrence (MK0462-022) rizatriptan benzoate (MK0462), Comparator: placebo - Migraine Headache | Phase 3 | Completed | Organon and Co | 1473 | 1995-03-01 | 2022-02-03 |
Migraine Disorders (17) · Migraine with Aura (1) · Migraine without Aura (1)
Organon and Co (14) · Axsome Therapeutics, Inc. (2) · Diamond Headache Clinic (1) · Eurofarma Laboratorios S.A. (1) · Merck Sharp & Dohme LLC (1) · Robert W. Baloh (1)
United States (4) · Brazil (1)
Frederick G Freitag, DO (1) · Robert W Baloh, M.D. (1)
PMID 11284464, PMID 11284463, PMID 11422095, PMID 21070230, PMID 21078681, PMID 22078129, PMID 22711898, PMID 23078588, PMID 40354049, PMID 9595867, PMID 9748025